Lantern Pharma Gains FDA Support for HARMONIC Trial Amendments in Never-Smoker Lung Cancer
Lantern Pharma announced FDA no objections to protocol amendments for its Phase 2 HARMONIC trial of LP-300 in never-smokers with advanced NSCLC, focusing on a specific EGFR mutation subgroup.
Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration raised no objections to proposed protocol amendments for the ongoing Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-small cell lung cancer (NSCLC) adenocarcinoma. The FDA's written response to the company's Type C meeting request provides a clearer regulatory path forward for the program, according to the company.
The amended strategy focuses on the EGFR exon 21 L858R-mutant never-smoker population, where emerging data suggest LP-300 may offer differentiated benefit in combination with standard chemotherapy following kinase inhibitor treatment failure. This targeted approach could address a significant unmet need, as never-smokers with EGFR mutations often develop resistance to first-line tyrosine kinase inhibitors (TKIs) and have limited subsequent treatment options.
Lantern Pharma is a clinical-stage precision oncology company leveraging artificial intelligence and machine learning through its proprietary RADR platform to transform cancer therapy development. The company's pipeline includes LP-184, LP-284, and LP-300, which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma after TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.
In addition to its clinical programs, Lantern has commercialized withZeta.ai, a multi-agentic AI co-scientist platform now available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
The FDA's support for the trial amendments is a critical step for Lantern, as it validates the company's precision medicine approach and could accelerate the development of LP-300 for a well-defined patient population. The news is particularly important given the high unmet need for effective treatments in never-smoker NSCLC patients with EGFR mutations who have progressed on TKI therapy. If successful, LP-300 could offer a new therapeutic option for this subgroup, potentially improving outcomes in a disease that remains a leading cause of cancer death worldwide.
For more information, visit the company's newsroom at https://ibn.fm/LTRN and the InvestorWire website at https://www.InvestorWire.com.